In the trial, participants are randomly assigned to either keep taking the medication right up to the morning of the surgery or to stop it three days before the procedure. The operation is performed using cardiopulmonary bypass, a technique that temporarily takes over the work of the heart and lungs. After surgery, patients are monitored for about a month to see whether they develop problems such as damage to the heart muscle measured by an increase in high-sensitivity troponin I, a blood test that shows heart injury, or experience low cardiac output syndrome, which means the heart is not pumping enough blood. Other complications that are checked include a rare condition called euglycaemic ketoacidosis (a buildup of acids despite normal blood sugar), acute renal failure (sudden kidney problems) assessed using the KDIGO scoring system, need for additional hospital stays for heart failure, and overall survival. The follow‑up period lasts 30 days after the surgery, during which length of hospital stay and quality of life are also recorded.

Participants are randomly assigned to either the active drug or placebo and will take the tablets daily for roughly 18 months alongside their cancer treatment. Heart function is measured at the start and at the end of the study using CMR, a special type of MRI that visualizes the heart. The primary assessment is the change in LVEF, which indicates how well the left side of the heart pumps blood. Additional evaluations include GLS, a measure of how the heart muscle stretches during beats, and blood tests for NT-proBNP and the high‑sensitivity cardiac injury markers hs‑TnI and hs‑TnT.

The study has two parts. The first part looks back at medical records to understand the current state of heart failure treatment and identify any differences in how men and women receive care. The second part is a forward-looking trial involving women between 18 and 85 years old who have been hospitalized for heart failure. These women will be divided into two groups: one group will receive increased doses of their heart failure medications following a specific treatment plan, while the other group will continue with their usual care. The study will track participants for 12 months to see how the different approaches affect their health.

During the study, researchers will measure several outcomes including death from any cause, hospital readmission for heart failure, and worsening heart failure symptoms. They will also assess quality of life using a questionnaire, how well participants stick to their medication, and any side effects experienced. Additional measurements will include changes in blood test markers and outcomes in specific groups of patients such as those with different levels of heart function, different ages, or those with diabetes, kidney disease, or obesity. The study aims to determine whether optimizing medication doses in women with heart failure can reduce illness and death, improve quality of life, and help identify the best treatment approach for this patient group.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The study will look at patients who have a specific type of heart failure where the heart’s ability to pump blood is only mildly reduced or preserved. Participants must have certain signs of heart failure, including elevated pressure in the heart chambers or previous hospital visits for heart failure symptoms. The study will measure how the treatment affects important aspects of the condition, such as physical function and quality of life.

Throughout the study, researchers will track any heart-related events, measure how far participants can walk in 6 minutes, and assess how participants feel in their daily activities. They will also monitor the levels of substances in the blood that indicate heart stress and keep track of any side effects that may occur during treatment. All participants must also be taking another type of medication called an SGLT2 inhibitor before and during the study.

The aim is to find out whether adding the new medication to standard treatment lowers the chance of dying from heart‑related causes, being hospitalized for heart failure, or needing urgent care for heart failure.

Participants will receive a dose once a week for several months and will attend regular visits where simple checks such as blood pressure, weight, and short questionnaires are done. The study follows each person over time to see how often the listed heart events occur and to monitor safety through routine lab tests.

The treatment being investigated is dapagliflozin propanediol monohydrate, which belongs to a class of drugs known as gliflozins. Participants in the study may receive this medication via oral use, meaning it is taken by mouth. Some participants will receive this early treatment along with telephone counseling, while others will receive standard care provided by the hospital. The study will monitor how well the treatment is accepted and followed over a period of time.

The purpose of the study is to see if finerenone can reduce levels of a substance in the blood called NT-proBNP, which is a marker that shows how well the heart is working. The study will also look at how safe finerenone is and how the body processes the medication. Participants in this study will be children from 6 months old up to 18 years old who have heart failure caused by various conditions such as heart defects present from birth, inherited heart muscle problems, inflammation of the heart muscle, certain muscle disorders, or other causes affecting the heart’s pumping ability. The children must already be taking standard medicines for heart failure for at least 30 days before joining the study.

During the study, participants will be assigned by chance to receive either finerenone or placebo in addition to their regular heart failure treatment. The treatment will last for 3 months, and doctors will measure various things including blood levels of NT-proBNP, potassium levels, blood pressure, kidney function, and heart function using ultrasound imaging of the heart. The study will also track any unwanted effects that occur and will monitor for serious heart-related events. Blood tests will be done to measure how much finerenone is in the body and how long it stays there. The entire study is expected to run from 2025 until the end of 2029.

This study is an extension study, which means some participants may join after completing a previous study with finerenone, while other newly enrolled infants under 6 months of age can join directly if they meet certain health requirements. During the study, participants will receive finerenone along with their regular heart failure medications. The study will monitor various safety measures including blood potassium levels, blood pressure, and kidney function, as well as checking for any unwanted effects of the treatment. The study will also measure levels of a substance called NT-proBNP in the blood, which is a marker of heart function, and will use imaging with echocardiography to see how well the heart is working.

The study will last for approximately 270 days for each participant. Throughout this time, regular visits will be scheduled to check the safety and effects of the treatment. Blood samples will be collected to measure how much finerenone is in the body. For participants using the granules for oral suspension, there will be questions about the taste and texture of this form of the medicine. The study will track any side effects or health changes that occur during treatment.

The purpose of this study is to find out if it is safe and possible to reduce or partially withdraw heart failure medications in patients whose hearts have recovered, compared to continuing all medications at the same doses. This will help doctors understand whether patients who have recovered from heart failure can safely take lower doses of their medications or stop some of them. The study will compare two groups of patients: one group will have some of their heart failure medications reduced while the other group will continue taking all their medications as before.

During the study, patients will be followed for up to 24 months. The study will measure several important things to see how well the heart is working and how patients are doing overall. Doctors will use heart ultrasound scans to check if the heart chambers change in size and will measure blood markers to monitor the heart’s condition. They will also track whether patients need to restart or increase their heart failure medications, how patients feel and function in their daily lives, and whether any serious health problems occur. The study will begin enrolling patients in October 2025 and is expected to be completed by March 2028.

The purpose of this research is to evaluate whether injecting these stem cells into the heart muscle is safe for patients with advanced heart failure. The treatment involves a surgical procedure where the cells are injected directly into specific areas of the heart that have been damaged by the previous heart attack. The study will monitor patients for any heart-related complications and track their overall health after receiving the treatment.

During the study, patients will receive the stem cell treatment along with their standard heart care. The research team will perform various tests to check heart function, including echocardiography (heart ultrasound) and magnetic resonance imaging (MRI) scans. Patients will be monitored regularly after the procedure to assess their recovery and any changes in their heart condition.

The study will test whether a medication called vicadrostat (BI 690517) when used in combination with another medication called empagliflozin is better than empagliflozin alone (with placebo) for treating heart failure. The purpose of the study is to determine if this combination therapy can reduce the occurrence of cardiovascular death, hospitalizations for heart failure, or urgent heart failure visits.

Participants in this study will be randomly assigned to receive either the combination of vicadrostat and empagliflozin or empagliflozin with placebo. The study will track outcomes such as cardiovascular events and measure heart failure symptoms using a questionnaire. This is a double-blind study, which means neither the participants nor the researchers will know which treatment each participant is receiving during the study.

The purpose of this study is to evaluate how different doses of COR-1167 compare to a placebo in treating worsening heart failure. COR-1167 is a Corticotrophin Releasing Factor 2 Agonist, which is a type of medication being investigated for its potential to help the body eliminate excess fluid and improve heart function. The medication will be given as a daily subcutaneous injection (under the skin) for 4 weeks.

During the study, researchers will monitor several factors including: how much urine participants produce (natriuresis), changes in body weight, levels of certain heart failure markers in the blood (NT-proBNP), heart failure symptoms using a questionnaire, and measurements of heart structure (specifically the Left Atrial Volume Index, which indicates how much the upper left chamber of the heart is enlarged). The study will also evaluate the safety of the medication by monitoring for side effects and checking laboratory values.

The purpose of this research is to determine if ziltivekimab is better than placebo at improving heart failure symptoms and physical function in people with this specific type of heart failure who also have inflammation. The study focuses on participants with NYHA Class II-III heart failure (a classification system where Class II means mild symptoms during ordinary activities and Class III means marked limitation of activity due to symptoms) and specific levels of inflammation markers in their blood.

During the 12-month study, participants will receive either ziltivekimab or placebo while continuing their standard heart failure treatments. Their heart failure symptoms, quality of life, and physical function will be assessed using questionnaires and a six-minute walk test (a test measuring how far someone can walk in six minutes). Blood tests will also be performed to measure markers of heart failure and inflammation.

The purpose of the study is to measure how quickly the heart takes up manganese, a component of the contrast agent, after it is administered. This will be done by using MRI to look at all parts of the left side of the heart. The study will include both healthy volunteers and patients with heart failure. Participants will receive the contrast agent through an injection, and their heart’s response will be monitored using MRI scans.

Throughout the study, researchers will compare the manganese uptake rates between healthy individuals and those with heart failure. They will also monitor for any side effects or changes in health indicators like vital signs and heart rhythms. The study aims to provide valuable insights into heart function in patients with heart failure and how it differs from healthy individuals.

The purpose of the study is to understand how the heart processes energy in patients with heart failure. This is done by using a technique called magnetic resonance imaging (MRI), which creates detailed images of the heart. The study aims to compare these images with other standard heart scans to see how well they match up.

Participants in the study will receive the injection of Hyperpolarized [1-13C]pyruvate and undergo MRI scans. The study will observe how the heart metabolizes the injected substance and will compare these findings with existing diagnostic methods. This research could provide new insights into heart function and potentially improve how heart failure is diagnosed and managed in the future.

The purpose of the study is to see if CDR132L can improve heart health by changing certain markers in the blood, specifically something called miR-132, over a period of 24 weeks. Participants will receive either CDR132L or a placebo, in addition to their usual heart failure treatments. The study will monitor changes in the heart’s structure and function, as well as any side effects, over the course of the trial.

Participants will be involved in the study for up to 60 weeks, during which they will have regular check-ups to assess their heart health and overall well-being. The study aims to provide valuable information on whether CDR132L can be a beneficial treatment for people with HFpEF and LVH, potentially leading to better management of these heart conditions in the future.

The purpose of the study is to determine if CDR132L is more effective than a placebo in improving heart health in participants. The study will last for several months, during which participants will receive either the CDR132L treatment or a placebo, in addition to their usual heart failure care. The main focus will be on changes in a specific molecule called miR-132 over a 24-week period. Participants will be monitored for any changes in their heart condition and any side effects they may experience.

Throughout the study, participants will undergo regular check-ups to assess their heart’s function and overall health. The study aims to provide valuable information on the potential benefits of CDR132L for people with heart failure and left ventricular hypertrophy, contributing to better treatment options in the future.

The study tests whether allopurinol, a medication that lowers uric acid levels in the blood, can help reduce the risk of cardiovascular events. Some participants will receive allopurinol tablets, while others will receive a placebo. The treatment will continue for approximately 5 years, during which participants will have regular check-ups to monitor their health status.

The main focus is to determine if allopurinol can prevent serious cardiovascular events such as heart problems, strokes, or the need for heart-related procedures. The study will also track other health changes, including heart function, blood vessel health, and the presence of long-COVID symptoms. Regular blood tests and heart examinations will be performed to monitor participants’ health throughout the study period.

The purpose of the study is to compare the effects of administering Furosemide Sodium directly into the abdominal cavity (intraperitoneally) versus taking it orally. The study will observe how this medication affects the body’s fluid levels and overall hydration status. Participants will receive the medication for a period of up to 30 days. During this time, various health indicators will be monitored, including body weight, blood pressure, and the presence of swelling (oedema). Advanced techniques like ultrasound and bioimpedance will be used to assess fluid levels in the body.

Additionally, the study will measure certain biochemical markers in the blood, such as CA125 and NT-proBNP, which can indicate fluid congestion in the body. The trial aims to provide valuable insights into the safety and effectiveness of using Furosemide Sodium in this new way, potentially offering improved treatment options for patients on peritoneal dialysis with heart failure.

The purpose of the study is to compare how these two medications affect the heart and blood vessels. Participants will receive either dobutamine or levosimendan, both administered intravenously, meaning they are given directly into a vein. The study will observe changes in the pressure within the lungs’ blood vessels and the amount of blood the heart pumps. These observations will help understand how each medication works in the current treatment context for heart diseases.

Throughout the study, participants will be monitored for various health indicators, including heart function and overall well-being. The study will last for a period of time, during which participants will have regular check-ups to assess their heart’s performance and any side effects from the medications. The goal is to gather information that could improve treatment options for people with heart failure.

The purpose of the study is to see if taking Entresto can prevent heart damage, specifically a decrease in the heart’s ability to pump blood, during breast cancer treatment. Participants in the study will be randomly assigned to receive either Entresto or a placebo. The study will last for 24 months, during which time participants will have regular check-ups and heart scans to monitor their heart health. These scans will include an ultrasound of the heart, which uses sound waves to create images of the heart’s structure and function.

Throughout the study, researchers will look for any changes in heart function, such as a decrease in the heart’s pumping ability, and will also monitor for any other heart-related issues. The goal is to determine if Entresto can effectively prevent heart damage in patients undergoing breast cancer treatment, potentially improving their overall health and quality of life during and after their cancer treatment.

Participants in the study will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The study will last for 12 weeks, during which time the effects of the treatment on cognitive function will be assessed. This will be done using a series of tests that measure different aspects of cognitive performance. The study will also look at changes in depression, anxiety, and quality of life over the course of the treatment.

In addition to the main focus on cognitive function, the study will also monitor changes in depression and anxiety levels, as well as overall quality of life. These aspects will be evaluated at the start of the study and again at 12 and 24 weeks to see if there are any improvements. The study aims to provide valuable information on how treating iron deficiency in patients with chronic heart failure can impact their mental and emotional well-being.

The purpose of the study is to see if the combination of BI 690517 and empagliflozin is more effective than empagliflozin alone in helping people with heart failure. Participants in the study will be randomly assigned to receive either the combination of BI 690517 and empagliflozin or a placebo and empagliflozin. The study will last for a period of 42 days, during which participants will take the medications orally, meaning they will swallow them in the form of tablets.

Throughout the study, researchers will monitor participants to see how the treatment affects their heart failure symptoms and overall health. The main focus will be on the time it takes for a participant to experience a serious heart-related event, such as a heart-related death or hospitalization due to heart failure. The study aims to provide valuable information on whether the new combination treatment can improve outcomes for people living with heart failure.

Participants in the study will receive either colchicine, thiamine, or a placebo. Colchicine is a medication commonly used to treat gout, while thiamine, also known as vitamin B1, is a vitamin that helps the body convert food into energy. The study will compare the effects of colchicine and thiamine on heart-related events, such as heart attacks or hospital visits due to heart failure, and overall heart health. The study will last for a period of time, during which participants will be monitored for any changes in their condition.

The purpose of this study is to determine if colchicine or thiamine can reduce the risk of serious heart-related events in people with heart failure due to ischemic heart disease. By participating in this study, researchers hope to gather valuable information that could lead to better treatment options for individuals with this condition in the future.

The treatment being studied is Conoxia, which is a medical-grade oxygen given in its liquid, extremely cold form (cryogenic). This pure oxygen will be administered to participants to examine its effects on blood circulation. The study will measure how the heart pumps blood and how blood vessels respond to this oxygen treatment.

During the study, measurements will be taken at different time points to see how quickly the body responds to the oxygen treatment. The study will look at blood flow changes in various parts of the body, including the heart’s small blood vessels and the blood vessels in the lungs. These measurements will help understand how oxygen treatment affects blood circulation throughout the body.

The purpose of the study is to assess how well dapagliflozin works in improving heart function and reducing changes in the heart’s structure over a period of six months. This will be done using a test called a transthoracic echocardiography (TTE), which is a type of ultrasound that looks at the heart. The study will monitor changes in the heart’s pumping ability and size, as well as other heart-related measurements. Participants will be followed for six months to see how their heart responds to the treatment.

Throughout the study, researchers will also keep track of any side effects or health changes that occur. This includes monitoring for symptoms like dehydration, low blood sugar, infections, and changes in kidney or liver function. The study will help determine if dapagliflozin can be a beneficial addition to standard heart attack treatments, potentially improving recovery and outcomes for patients with heart failure following a heart attack.

Participants in the study will receive either XXB750 or a placebo over a period of 16 weeks. The study aims to find the best dose of XXB750 that can help reduce the levels of NT-proBNP, which is a marker used to assess heart failure severity. Patients will continue to receive their standard heart failure treatments, such as ACE inhibitors or ARBs, which are common medications used to manage heart failure symptoms.

The trial will monitor changes in NT-proBNP levels and assess any side effects or changes in health during the study period. This research is important to determine if XXB750 can be a beneficial addition to existing heart failure treatments, potentially improving the quality of life for those affected by this condition.

The purpose of this study is to monitor the safety and tolerability of Vericiguat, also known by its code name MK-1242. Participants in this study will have previously been part of an earlier study and will continue to receive Vericiguat. The study will observe participants over a period to see if they experience any side effects or need to stop the treatment due to any adverse effects. The study will also look at changes in a specific heart-related protein in the blood, known as N-terminal pro-brain natriuretic peptide (NT-proBNP), which can indicate how well the heart is functioning.

Participants will take Vericiguat by mouth, either as a tablet or a liquid, for a maximum period of 108 weeks. The study aims to ensure that the treatment is safe and well-tolerated by the participants. This trial is an extension of a previous study, allowing researchers to gather more information about the long-term effects of Vericiguat in children with heart failure due to left ventricular systolic dysfunction.

The purpose of the study is to assess how Empagliflozin affects the heart’s function over a period of six months. Participants will be monitored to see if there are any changes in the size of the heart’s left atrium, which is a chamber of the heart, using a method called Cardiac Magnetic Resonance (CMR). This method provides detailed images of the heart to help doctors understand its structure and function. Additionally, the study will explore the use of Fitbit devices and mobile health technology to encourage exercise among participants, as regular physical activity is known to support heart health.

Throughout the study, participants will take Empagliflozin daily and undergo regular check-ups to monitor their heart’s condition. The study will last for six months, during which various heart-related measurements will be taken to evaluate any changes. This research aims to provide insights into whether Empagliflozin can be beneficial for heart health in people who are at risk of heart failure but do not have diabetes.

Participants in the study will be those who have been diagnosed with heart failure for over a year and have shown improvement in their heart’s ability to pump blood. The study will compare two groups: one group will stop taking beta-blockers, while the other will continue their medication. The trial will monitor the participants over a period ranging from one to four years to observe any changes in their heart condition, including any return of heart failure symptoms or other cardiovascular events.

In addition to beta-blockers, the study will also consider the effects of other medications commonly used in heart failure treatment, such as ACE inhibitors, Angiotensin II receptor blockers (ARBs), and SGLT2 inhibitors. These medications help manage heart failure by different mechanisms, such as relaxing blood vessels or helping the body remove excess glucose. The trial will assess the overall health and quality of life of participants, including any side effects from stopping beta-blockers, to determine the best approach for managing heart failure in patients with improved heart function.

Participants in the study will be randomly assigned to receive either the combination of Balcinrenone and Dapagliflozin or Dapagliflozin alone. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know which treatment each participant is receiving. This helps ensure the results are unbiased. The treatment will be administered in the form of capsules or tablets taken orally.

The study will last for a period of up to 38 weeks, during which participants will be monitored for any heart failure events, hospitalizations, or cardiovascular deaths. The goal is to see if the combination treatment can better prevent these outcomes compared to the single medication. Participants will have regular check-ups to assess their health and the effectiveness of the treatment. The study is expected to provide valuable insights into improving care for patients with heart failure and kidney issues.

The purpose of this study is to assess how Entresto affects the heart’s function in these patients. Participants in the study will take Entresto in the form of film-coated tablets, which are taken orally. The study will last for about six months, during which time the effects of the medication on heart function will be monitored. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active substances.

Throughout the study, various tests will be conducted to evaluate heart function, including a combination of exercise testing and imaging techniques. These tests will help determine how the medication affects the heart’s ability to pump blood and the severity of the mitral valve regurgitation. The study will also look at changes in participants’ quality of life and other health indicators. The goal is to better understand how Entresto can help manage these heart conditions and improve patient outcomes.

The purpose of the study is to see how effective these two medications are in reducing the risk of death in patients with heart failure who have a reduced ejection fraction. Ejection fraction is a measurement of how much blood the left ventricle of the heart pumps out with each contraction. Patients participating in the study will be monitored over a period of time to observe the effects of the medications on their heart health.

During the study, participants will receive either spironolactone, eplerenone, or a placebo. The study will track the occurrence of death or hospitalization due to heart failure as key outcomes. This research will help determine if spironolactone and eplerenone are comparable in their effectiveness for treating heart failure. The study is expected to continue until the end of 2028.

Participants in the study will have their medications gradually reduced and monitored over a period of up to 12 months. During this time, doctors will closely observe any changes in heart function and overall health. The study aims to see if patients can maintain their improved heart function without the need for these medications. This will be done by checking heart function through imaging tests and monitoring for any signs of heart failure returning.

The study will also look at other health aspects, such as changes in blood pressure, heart rate, and quality of life. Participants will be asked to complete questionnaires about their daily life and well-being. The goal is to gather information that could help improve treatment strategies for heart failure patients in the future.

The purpose of this study is to determine which of these two medications is more effective in reducing the risk of death from any cause or the first hospitalization due to worsening heart failure. Participants in the study will be patients who are already being treated for heart failure and have been prescribed either Carvedilol or Metoprolol succinate. The study will follow these patients over a period of time to observe the outcomes of their treatment.

Throughout the study, researchers will monitor the participants to see if there is a difference in the effectiveness of the two medications. The main focus will be on whether the patients experience any hospitalizations due to worsening heart failure or any other cause of death. This information will help doctors understand which medication might be better for treating heart failure with reduced ejection fraction. The study is expected to continue until 2029, providing valuable insights into the management of heart failure.

Participants in the study will be randomly assigned to receive either AZD3427 or a placebo, which looks like the treatment but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations. The study will take place over several months, with regular check-ups to monitor the participants’ health and the effects of the treatment.

The main goal is to see if AZD3427 can improve the condition of the blood vessels in the lungs, which is measured by a test called right heart catheterization. This test helps doctors see how well the heart and lungs are working together. The study will also look at other health indicators, such as heart function and exercise capacity, to understand the overall impact of the treatment. Participants will be closely monitored throughout the study to ensure their safety and well-being.

Participants in the study will be women who have early-stage heart failure or a condition known as diastolic dysfunction, where the heart has trouble relaxing and filling with blood. The study aims to see if using Perindopril can help reverse changes in the heart that occur in these conditions, bringing them closer to healthy values. The trial will also involve monitoring other aspects of health, such as blood pressure and quality of life, to understand the broader effects of the treatment.

During the study, participants will take Perindopril in the form of tablets, and their progress will be observed over the two-year period. The goal is to gather information on how effective the medication is in improving heart health and overall well-being in women with early signs of heart failure. This research could provide valuable insights into managing heart conditions before they become more serious.

Participants in the study will be monitored over a period of time to see how digoxin affects their heart health. The study will look at various outcomes, such as the number of times participants are hospitalized for heart failure, the number of urgent heart-related hospital visits, and overall heart-related deaths. Additionally, the study will assess the overall quality of life and any side effects experienced by participants taking digoxin.

The trial will also explore other aspects, such as the impact of digoxin on heart rate and the occurrence of a condition called atrial fibrillation (AF), which is an irregular and often rapid heart rate. The study aims to provide valuable insights into the effectiveness and safety of digoxin for managing chronic heart failure.

The study involves three groups of participants. One group will receive a low dose of CDR132L, another group will receive a higher dose, and the third group will receive a placebo. The treatment is given through an intravenous infusion, which means it is administered directly into the bloodstream. Participants will receive three doses, each given 28 days apart. The study will monitor changes in heart function and overall health over a period of time to determine the impact of the treatment.

Throughout the study, participants will undergo various health assessments, including heart imaging tests and blood tests, to track their progress. The goal is to see if CDR132L can help improve heart function and reduce symptoms associated with heart failure after a heart attack. The study will also keep track of any side effects or health changes experienced by participants to ensure the treatment is safe.